Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript

Seeking Alpha • 4 hours ago

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its.

Business Wire • 12 hours ago

Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.85 per share a year ago.

Zacks Investment Research • 8 hours ago

Top 5 Bargain P/B Stocks Investors Should Watch Now

AES joins four other low P/B stocks that screen for value, growth and liquidity, offering investors undervalued picks to watch in February.

Zacks Investment Research • Feb 18, 2026

4 Value Stocks to Buy Now Amid AI-Driven Market Volatility

Value stocks are back in focus as markets remain steady. HRMY, TRIP, AES and CNXC screen cheap on P/CF, offering growth and cash flow strength.

Zacks Investment Research • Feb 18, 2026

Earnings Preview: Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Expected to Decline

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 17, 2026

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of cataplexy in pediatric patients 6 years of age and older with narcolepsy. WAKIX is now the first-and-only FDA-approved non-scheduled treatment for pediatric and adult narcolepsy patients with or without cataplexy. “We are excited to achieve this im.

Business Wire • Feb 17, 2026

3 Reasons Why Growth Investors Shouldn't Overlook Harmony Biosciences (HRMY)

Harmony Biosciences (HRMY) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Investment Research • Feb 16, 2026

Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally 26.95%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 27% in Harmony Biosciences (HRMY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Investment Research • Feb 12, 2026

Is Harmony Biosciences (HRMY) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Investment Research • Feb 11, 2026